Jake Weddell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jake Weddell has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Helena Marzo-Ortega
NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
7 shared publications - Dennis McGonagle
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
5 shared publications - Pedro M. Machado
Department of Neuromuscular Diseases, University College London, London, UK
3 shared publications Andrew Barr
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
2 shared publications- Andrew Barr
NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds
2 shared publications - Claire Vandevelde
NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds
2 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (5) , 106079
Two Patterns of Sacroiliac Joint Bone Marrow Oedema are apparent in AxSpA Determined by HLA-B27 Status, Body Mass Index or Psoriasis
- 26 May 2026
- Published by Elsevier in Joint Bone Spine
- Vol. 93 (5) , 106079
Open AccessTwo Patterns of Sacroiliac Joint Bone Marrow Oedema are apparent in AxSpA Determined by HLA-B27 Status, Body Mass Index or Psoriasis
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2)
Better communication between rheumatologists and radiologists is key to improving MRI requesting and reporting data in axial spondyloarthritis: audit data from a single specialist centre
Objectives: The assessment of axial spondyloarthritis international society (ASAS) has published recommendations on information to include when requesting and reporting MRIs for suspected or known axSpA. In a service improvement evaluation, we aimed to audit our current practice against the newly published recommendations. Methods: MRIs of the spine and sacroiliac joints performed under the inflammatory back pain protocol at The Leeds Teaching Hospitals NHS Trust between September and December 2023 were identified. Information included in the MRI request and radiology reports was extracted from the electronic health records. Results: Overall, 158 MRIs were evaluated. Of the MRI requests, age was included in 11.8% (n = 18), sex in 3.8% (n = 6); HLA-B27 in 22.2% (n = 35), back pain symptom duration in 18.9% (n = 30) and location in 45.6% (n = 72) and presence of inflammatory features in 62.7% (n = 99). For MRI report data: osteitis/bone marrow oedema was mentioned in 81.0% (n = 128), erosions in 58.8% (n = 93) and fat metaplasia in 6.3% (n = 10); active inflammation was mentioned in 77.8% (n = 123) and structural changes in 51.2% reports (n = 82). Over half (62.0%; n = 98) included a statement as to “whether the MRI was overall indicative of spondyloarthritis or not”. Conclusion: Despite the retrospective nature of this audit performed against newly published guidance, these results provide awareness, identifying key areas in need of improvement at our centre. Further, this exercise has strengthened the collaboration between rheumatologists and radiology colleagues, illustrating the value of the recent ASAS recommendations as a benchmark to guide further training and education for rheumatologists and radiologists, and improve clinical care provision in axSpA.
- 18 March 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (2)
Open AccessBetter communication between rheumatologists and radiologists is key to improving MRI requesting and reporting data in axial spondyloarthritis: audit data from a single specialist centre
Objectives: The assessment of axial spondyloarthritis international society (ASAS) has published recommendations on information to include when requesting and reporting MRIs for suspected or known axSpA. In a service improvement evaluation, we aimed to audit our current practice against the newly published recommendations. Methods: MRIs of the spine and sacroiliac joints performed under the inflammatory back pain protocol at The Leeds Teaching Hospitals NHS Trust between September and December 2023 were identified. Information included in the MRI request and radiology reports was extracted from the electronic health records. Results: Overall, 158 MRIs were evaluated. Of the MRI requests, age was included in 11.8% (n = 18), sex in 3.8% (n = 6); HLA-B27 in 22.2% (n = 35), back pain symptom duration in 18.9% (n = 30) and location in 45.6% (n = 72) and presence of inflammatory features in 62.7% (n = 99). For MRI report data: osteitis/bone marrow oedema was mentioned in 81.0% (n = 128), erosions in 58.8% (n = 93) and fat metaplasia in 6.3% (n = 10); active inflammation was mentioned in 77.8% (n = 123) and structural changes in 51.2% reports (n = 82). Over half (62.0%; n = 98) included a statement as to “whether the MRI was overall indicative of spondyloarthritis or not”. Conclusion: Despite the retrospective nature of this audit performed against newly published guidance, these results provide awareness, identifying key areas in need of improvement at our centre. Further, this exercise has strengthened the collaboration between rheumatologists and radiology colleagues, illustrating the value of the recent ASAS recommendations as a benchmark to guide further training and education for rheumatologists and radiologists, and improve clinical care provision in axSpA.
- Open Access
Utility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres
Introduction: The role of MRI of the spine/sacroiliac joints to aid the diagnosis of axial spondyloarthritis (axSpA) is well established. Limited data, however, exist on the use of MRI to assess disease activity, resulting in current Assessment of SpondyloArthritis International Society (ASAS)/European Alliance of Associations for Rheumatology (EULAR) guidelines not recommending the use of MRI for this purpose. We aimed to assess the current use of MRI to assess disease activity and its impact on clinical decision making. Methods: As part of a service evaluation, we identified patients with a prior diagnosis of axSpA, who had an MRI of the spine/sacroiliac joints requested between May 2020 and December 2023 at The Leeds Teaching Hospitals Trust (Leeds) and Northwick Park Hospital (London). Clinical and demographic data were extracted from the medical notes. Data on MRI findings were extracted from the radiologist’s report. Results: Overall, 346 scans were performed in 335 patients. 301 patients had axSpA (170 radiographic axSpA, 131 non-radiographic axSpA) and 31 axial psoriatic arthritis. Patients were predominantly male (60.0%) and HLA-B27 positive (60.6%). 140/172 (80.1%) of patients had evidence of inflammation on a pre-treatment MRI scan. 224 scans (64.7%) were performed in patients on biologic/targeted synthetic disease-modifying antirheumatic drugs. Of the 346 MRIs performed during the audit period, 179 (54.7%) had evidence of active inflammation and those with active inflammation were more likely to have their treatment escalated (59.3% vs 23.2%). Conclusions: MRI is of utility in assessing disease activity with results of MRI scans directly influencing treatment decision making at the bedside. Further research exploring the relationship between MRI findings and clinical outcomes is warranted.
Open AccessUtility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres
Introduction: The role of MRI of the spine/sacroiliac joints to aid the diagnosis of axial spondyloarthritis (axSpA) is well established. Limited data, however, exist on the use of MRI to assess disease activity, resulting in current Assessment of SpondyloArthritis International Society (ASAS)/European Alliance of Associations for Rheumatology (EULAR) guidelines not recommending the use of MRI for this purpose. We aimed to assess the current use of MRI to assess disease activity and its impact on clinical decision making. Methods: As part of a service evaluation, we identified patients with a prior diagnosis of axSpA, who had an MRI of the spine/sacroiliac joints requested between May 2020 and December 2023 at The Leeds Teaching Hospitals Trust (Leeds) and Northwick Park Hospital (London). Clinical and demographic data were extracted from the medical notes. Data on MRI findings were extracted from the radiologist’s report. Results: Overall, 346 scans were performed in 335 patients. 301 patients had axSpA (170 radiographic axSpA, 131 non-radiographic axSpA) and 31 axial psoriatic arthritis. Patients were predominantly male (60.0%) and HLA-B27 positive (60.6%). 140/172 (80.1%) of patients had evidence of inflammation on a pre-treatment MRI scan. 224 scans (64.7%) were performed in patients on biologic/targeted synthetic disease-modifying antirheumatic drugs. Of the 346 MRIs performed during the audit period, 179 (54.7%) had evidence of active inflammation and those with active inflammation were more likely to have their treatment escalated (59.3% vs 23.2%). Conclusions: MRI is of utility in assessing disease activity with results of MRI scans directly influencing treatment decision making at the bedside. Further research exploring the relationship between MRI findings and clinical outcomes is warranted.
- Open Access
- 14 September 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (4) , rkae139
Current usage of and perspectives on the use of MRI to assess treatment non-response in axial spondyloarthritis: a UK-based survey
Jake Weddell, Timothy JP Bray, Raj Sengupta, Dennis McGonagle, Pedro M Machado, Helena Marzo-Ortega; Current usage of and perspectives on the use of MRI to
- 14 September 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (4) , rkae139
Open AccessCurrent usage of and perspectives on the use of MRI to assess treatment non-response in axial spondyloarthritis: a UK-based survey
Jake Weddell, Timothy JP Bray, Raj Sengupta, Dennis McGonagle, Pedro M Machado, Helena Marzo-Ortega; Current usage of and perspectives on the use of MRI to
- Open Access
- 7 June 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (3) , rkae087
British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis
Objectives: Timely diagnosis remains a challenge in axial SpA (axSpA). In addition, data are scarce on the impact of diagnostic delay and disease progression in affected individuals. The British Axial Spondyloarthritis Inception Cohort (BAxSIC) study aims to investigate the impact of newly diagnosed axSpA, the natural history of the disease and the effect of diagnostic delay on disease outcomes. Methods: BAxSIC is a prospective, multicentre, observational study. Eligible participants are adults (≥16 years of age), with a physician-confirmed diagnosis of axSpA in the 6 months prior to study entry, recruited from secondary and tertiary rheumatology centres in the UK. Participants will be followed up for 3 years, with in-person visits at baseline and 24 months. In addition, patient self-reported assessments will be recorded remotely via the online electronic case report form (eCRF) at 6, 12, 18, 30 and 36 months. Results: The first patient was enrolled in BAxSIC in June 2023. Recruitment is currently ongoing and is planned to end in June 2026. Initial results will be available in 2027. Since opening, the trial has undergone two protocol amendments. Conclusion: The BAxSIC study is the first inception cohort designed to investigate the impact of diagnostic delay on clinical presentation and long-term functional outcomes in patients with axSpA in the UK. With an innovative, patient-led virtual longitudinal data collection model, data generated from this study will help inform and improve the care of people newly diagnosed with axSpA. Trial registration: ClinicalTrials.gov (http://clinicaltrials.gov), NCT05676775.
- 7 June 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (3) , rkae087
Open AccessBritish Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis
Objectives: Timely diagnosis remains a challenge in axial SpA (axSpA). In addition, data are scarce on the impact of diagnostic delay and disease progression in affected individuals. The British Axial Spondyloarthritis Inception Cohort (BAxSIC) study aims to investigate the impact of newly diagnosed axSpA, the natural history of the disease and the effect of diagnostic delay on disease outcomes. Methods: BAxSIC is a prospective, multicentre, observational study. Eligible participants are adults (≥16 years of age), with a physician-confirmed diagnosis of axSpA in the 6 months prior to study entry, recruited from secondary and tertiary rheumatology centres in the UK. Participants will be followed up for 3 years, with in-person visits at baseline and 24 months. In addition, patient self-reported assessments will be recorded remotely via the online electronic case report form (eCRF) at 6, 12, 18, 30 and 36 months. Results: The first patient was enrolled in BAxSIC in June 2023. Recruitment is currently ongoing and is planned to end in June 2026. Initial results will be available in 2027. Since opening, the trial has undergone two protocol amendments. Conclusion: The BAxSIC study is the first inception cohort designed to investigate the impact of diagnostic delay on clinical presentation and long-term functional outcomes in patients with axSpA in the UK. With an innovative, patient-led virtual longitudinal data collection model, data generated from this study will help inform and improve the care of people newly diagnosed with axSpA. Trial registration: ClinicalTrials.gov (http://clinicaltrials.gov), NCT05676775.
- Open Access
- 9 December 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (1) , rkae018
Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis
Objective: The aim was to assess the use and drug survival of IL-17Ai in a real-world cohort of axial SpA (axSpA) and PsA patients. Methods: Patients ever commenced on an IL-17Ai (secukinumab or ixekizumab) for axSpA or PsA at the Leeds Specialist Spondyloarthritis Service were identified. Demographics, IL-17Ai treatment length and reason for cessation were collected. Drug survival data were plotted as a Kaplan–Meier curve, with log rank test of median survival compared between axSpA and PsA. Cox regression analysis was performed to investigate the relationship between diagnosis and length of drug survival. Results: In total, 228 patients (91 axSpA and 137 PsA) were exposed to IL-17Ai. Drug survival for all patients at 12 months was 69% (95% Confidence Interval (CI) 63, 75%) and at 24 months 60% (95% CI 54, 67%). In axSpA and PsA, drug survival at 12 months was 63% (CI 54, 74%) and 73% (CI 66, 81%), respectively, and at 24 months it was 53% (CI 44, 65%) and 65% (CI 57, 75%), respectively. Median survival did not differ significantly between both diseases (log rank test 0.65). There was no association between diagnosis and survival (hazard ratio 0.92, 95% CI 0.63, 1.33), including when adjusting for age, previous biologic DMARD usage and sex (hazard ratio 0.89, 95% CI 0.61, 1.13). Conclusion: This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.
- 9 December 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (1) , rkae018
Open AccessReal-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis
Objective: The aim was to assess the use and drug survival of IL-17Ai in a real-world cohort of axial SpA (axSpA) and PsA patients. Methods: Patients ever commenced on an IL-17Ai (secukinumab or ixekizumab) for axSpA or PsA at the Leeds Specialist Spondyloarthritis Service were identified. Demographics, IL-17Ai treatment length and reason for cessation were collected. Drug survival data were plotted as a Kaplan–Meier curve, with log rank test of median survival compared between axSpA and PsA. Cox regression analysis was performed to investigate the relationship between diagnosis and length of drug survival. Results: In total, 228 patients (91 axSpA and 137 PsA) were exposed to IL-17Ai. Drug survival for all patients at 12 months was 69% (95% Confidence Interval (CI) 63, 75%) and at 24 months 60% (95% CI 54, 67%). In axSpA and PsA, drug survival at 12 months was 63% (CI 54, 74%) and 73% (CI 66, 81%), respectively, and at 24 months it was 53% (CI 44, 65%) and 65% (CI 57, 75%), respectively. Median survival did not differ significantly between both diseases (log rank test 0.65). There was no association between diagnosis and survival (hazard ratio 0.92, 95% CI 0.63, 1.33), including when adjusting for age, previous biologic DMARD usage and sex (hazard ratio 0.89, 95% CI 0.61, 1.13). Conclusion: This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.
- Open Access
- 22 October 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (2) , 285-290
What non-pharmacological treatments do people with polymyalgia rheumatica try: results from the PMR Cohort Study
Polymyalgia rheumatica (PMR) is common. The mainstay of treatment, glucocorticoids, are associated with significant adverse effects and many patients remain on high doses for a number of years. Little is known about the use of other, non-pharmacological therapies as adjuncts in PMR. The PMR Cohort Study is an inception cohort study of patients diagnosed with PMR in primary care. This analysis presents data on the use and perceived impact of non-pharmacological therapies from a long-term follow-up survey. Non-pharmacological treatments were classified as either diet, exercise, or complementary therapies. Results are presented as adjusted means, medians, and raw counts where appropriate. One hundred and ninety-seven participants completed the long-term follow-up questionnaire, of these 81 (41.1%) reported using non-pharmacological therapy. Fifty-seven people reported using a form of complementary therapy, 35 used exercise and 20 reported changing their diet. No individual non-pharmacological therapy appeared to be associated with long-term outcomes. The use of non-pharmacological therapies is common amongst PMR patients, despite the paucity of evidence supporting their use. This suggests that people perceive a need for treatment options in addition to standard glucocorticoid regimens. Further research is needed to understand patients’ aims when seeking additional treatments and to strengthen the evidence base for their use so that patients can be guided towards effective options.
- 22 October 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (2) , 285-290
Open AccessWhat non-pharmacological treatments do people with polymyalgia rheumatica try: results from the PMR Cohort Study
Polymyalgia rheumatica (PMR) is common. The mainstay of treatment, glucocorticoids, are associated with significant adverse effects and many patients remain on high doses for a number of years. Little is known about the use of other, non-pharmacological therapies as adjuncts in PMR. The PMR Cohort Study is an inception cohort study of patients diagnosed with PMR in primary care. This analysis presents data on the use and perceived impact of non-pharmacological therapies from a long-term follow-up survey. Non-pharmacological treatments were classified as either diet, exercise, or complementary therapies. Results are presented as adjusted means, medians, and raw counts where appropriate. One hundred and ninety-seven participants completed the long-term follow-up questionnaire, of these 81 (41.1%) reported using non-pharmacological therapy. Fifty-seven people reported using a form of complementary therapy, 35 used exercise and 20 reported changing their diet. No individual non-pharmacological therapy appeared to be associated with long-term outcomes. The use of non-pharmacological therapies is common amongst PMR patients, despite the paucity of evidence supporting their use. This suggests that people perceive a need for treatment options in addition to standard glucocorticoid regimens. Further research is needed to understand patients’ aims when seeking additional treatments and to strengthen the evidence base for their use so that patients can be guided towards effective options.
- Open Access
- 1 September 2020
- Published by Springer Nature in BMC Neurology
- Vol. 20 (1) , 1-9
Mechanical thrombectomy: can it be safely delivered out of hours in the UK?
Background: Mechanical thrombectomy was approved by NICE as a treatment for stroke in 2016. However, most of the evidence is from studies conducted during working hours. Only few centres in the UK perform thrombectomies out-of-hours. The Royal Stoke University Hospital (RSUH) has offered thrombectomies over 24 h (24/7) since 2010. The aim of this service review is to compare the outcomes for patients treated in regular working hours to those treated outside normal working hours within this unit. Methods: This retrospective service analysis includes all patients treated with mechanical thrombectomy at RSUH since the start of the service in January 2010 to June 2019. Data on key demographics, timings, procedural complications, and long-term outcomes including death and disability at 90 days were collected. In-hours was defined as the time between 8:00–17:00 h, Monday to Friday; out-of-hours was defined as any time outside this period. Results: In total, 516 mechanical thrombectomies were performed in this time period; data were available on 501 of these. Successful recanalization (TICI 2b/3) was achieved in 86% of patients. By 90 days 96 (19%) had died and 234 (47%) were functionally independent (modified Rankin Scale score ≤ 2). 211 (42%) of the procedures were performed in-hours and 290 (58%) out-of-hours. Door-to-CT and door-to-groin times were significantly longer out-of-hours than in-hours, but thrombectomy duration was significantly shorter. There were no significant differences in complications and short- and long-term outcomes. Conclusion: Mechanical thrombectomy was delivered safely and effectively 24/7 in this UK hospital, with no difference in clinical outcomes.
- 1 September 2020
- Published by Springer Nature in BMC Neurology
- Vol. 20 (1) , 1-9
Open AccessMechanical thrombectomy: can it be safely delivered out of hours in the UK?
Background: Mechanical thrombectomy was approved by NICE as a treatment for stroke in 2016. However, most of the evidence is from studies conducted during working hours. Only few centres in the UK perform thrombectomies out-of-hours. The Royal Stoke University Hospital (RSUH) has offered thrombectomies over 24 h (24/7) since 2010. The aim of this service review is to compare the outcomes for patients treated in regular working hours to those treated outside normal working hours within this unit. Methods: This retrospective service analysis includes all patients treated with mechanical thrombectomy at RSUH since the start of the service in January 2010 to June 2019. Data on key demographics, timings, procedural complications, and long-term outcomes including death and disability at 90 days were collected. In-hours was defined as the time between 8:00–17:00 h, Monday to Friday; out-of-hours was defined as any time outside this period. Results: In total, 516 mechanical thrombectomies were performed in this time period; data were available on 501 of these. Successful recanalization (TICI 2b/3) was achieved in 86% of patients. By 90 days 96 (19%) had died and 234 (47%) were functionally independent (modified Rankin Scale score ≤ 2). 211 (42%) of the procedures were performed in-hours and 290 (58%) out-of-hours. Door-to-CT and door-to-groin times were significantly longer out-of-hours than in-hours, but thrombectomy duration was significantly shorter. There were no significant differences in complications and short- and long-term outcomes. Conclusion: Mechanical thrombectomy was delivered safely and effectively 24/7 in this UK hospital, with no difference in clinical outcomes.